Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer
Brief Summary: This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept.

The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg and 2.0 mg/kg, administered intravenously (IV) every 2 weeks with historical control in participants with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin.

The secondary objectives was to further assess efficacy, safety, pharmacokinetics, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life.

This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. If an endpoint was evaluated by the IRC, the IRC reviewed data is reported for this study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo
B: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
C: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
D: Arm Label: Farletuzumab; Type: EXPERIMENTAL; Interventions: Drug: Farletuzumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Farletuzumab; Assigned to Arm(s): Farletuzumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C